Kevin Joseph Fitzgerald Sells 1,440 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Friday, February 14th, Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $255.21, for a total value of $169,204.23.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $250.51 on Thursday. The firm has a market cap of $32.43 billion, a P/E ratio of -115.44 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The business’s 50 day moving average is $253.89 and its 200-day moving average is $263.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, February 14th. Scotiabank dropped their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday, February 14th. Sanford C. Bernstein dropped their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Chardan Capital reiterated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, HC Wainwright restated a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $299.48.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Capital World Investors grew its position in Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock worth $3,906,284,000 after buying an additional 92,101 shares in the last quarter. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock worth $2,996,296,000 after buying an additional 98,303 shares in the last quarter. Capital Research Global Investors grew its position in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock worth $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock valued at $1,031,705,000 after purchasing an additional 1,245,195 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.